Thymidylate synthase (TS) catalyzes the conversion of 2Ј-deoxyuridine-5Ј-monophosphate (dUMP) to 2Ј-deoxythymidine-5Ј-monophosphate (dTMP) and is essential for de novo DNA biosynthesis.
We previously reported that N-[4-[3-(2,4-diamino-7H-
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After extensive chemical modification of pyrrolo [2,3-d] pyrimidine antifolates, [8] [9] [10] [11] [12] ) the 4-oxo compounds (2, 3) were found to moderately inhibit TS (IC 50 ϭ4.7, 1.4 mM, respectively). 8) Taylor and co-workers independently reported the synthesis and TS inhibitory activity of compound 2 (LY231514) as a 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF) 13) analogue. 14) Clinical trials of LY231514 are underway. 15) The 3D (three-dimensional) structure of E. coli TS-dUMP-CB3717 ternary complex has been determined by X-ray crystallography.
16) The structural information of TS enabled us to design potent TS inhibitors of pyrrolo [2,3-d] pyrimidine using molecular modeling techniques. Agouron's group reported the drug design and synthesis of a new class of TS inhibitors by an iterative crystallographic analysis of an E. coli TS-dUMP-inhibitor ternary complex. 17) Although their iterative process is a useful strategy for ligand design, it usually takes considerable time to isolate and to solve the crystallized structure of the complex. In addition, their design was carried out on TS from E. coli. The sequence of E. coli TS at the active site has high homology (75% identity) to the human sequence (Fig. 2 ), but we thought it would be advantageous for an accurate design to use a human TS model. Thus, to explore novel TS inhibitors we built a human TS-dUMP-inhibitor complex model on the basis of the reported E. coli TS-dUMP-CB3717 ternary complex. 16) Here we report our design and the synthesis of unique pyrrolo [2,3-d] pyrimidine derivatives with one-carbon bridge and their potent inhibitory activities against TS.
Design When we started our research, the 3D structure of human TS was not available. Thus, the 3D model of human TS was built by comparative modeling techniques using the amino acid sequence of human TS and the crystal structure of the reported E. coli TS-dUMP-CB3717 ternary complex. 16, 18) After dUMP and CB3717 were docked manually according to the crystal structure, the energy of the complex model was minimized with moderate constraints on the backbone and dUMP. 19) In human TS, the enzyme-ligand interactions might be altered by three replacements around the active site region [Glu82 (E. coli)→Ala (human), Trp83 (E. coli)→Asn (human) and Val262 (E. coli)→Met (human)]. (The numbering of the human TS model corresponds to that of E. coli TS.) The replacement of Trp83→Asn would introduce hydrogen-bonding sites, while the replacements of Glu82→Ala and Val262→Met would alter hydrophobic interactions. After our research was completed, three crystal structures of human TS complexed with its inhibitors have become accessible from the Protein Data Bank. 20) Comparison of the crystal structures by superimposing the backbones demonstrated that the active site structure of our human TS model was consistent with that of the crystal structures and suitable for structure-based drug design. 21) We started the drug design by studying the binding mode of CB3717 in the human TS model (Fig. 3a) . Its binding factors were speculated to include three hydrogen-bonding interactions between 2-NH 2 and Ala263, 3-NH and Asp169, and 4-O and Gly173. The p-aminobenzoyl and propargyl moieties contributed to the hydrophobic interactions with Ile79, Leu172, Pro175 and Phe176. Aromatic ring stacking interactions were also present between the quinazolinone and the pyrimidine of dUMP. In addition, a hydrophobic cavity surrounded by Glu58, Trp80 and the propargyl moiety was observed (Fig. 3b) .
We then focused our attention on the design of novel pyrrolo [2,3-d] pyrimidine derivatives as TS inhibitors, based on the information from the human TS-dUMP-CB3717 ternary complex model. A docking study of compound 2 (LY231514) with the human TS model suggested that the hydrogen-bond between 4-O and Gly173 was absent while the hydrophobic interactions of the benzoyl moiety were preserved. These results led us to speculate that the pyrrolo [2,3-d] pyrimidine ring moved from the position of the quinazoline of CB3717, because the benzoyl moiety was accommodated into the hydrophobic pocket (Fig. 4) . This could be caused by the replacement of the quinazoline ring with the pyrrolo [2,3-d] pyrimidine ring and the deletion of the propargyl moiety. Using this information, we replaced the two-carbon bridge of compound 2 with a one-carbon bridge (compound 4) to restore the important binding factors, that is, three hydrogenbonds (between 2-NH 2 and Ala263, 3-NH and Asp169, and 4-O and Gly173) and the hydrophobic interactions of the benzoyl moiety with the enzyme. Actually, when the binding mode of 4 in the human TS model was examined, three hydrogen-bonds of the pyrrolo [2,3-d] pyrimidine system, hydrophobic interactions of the benzene moiety, and ring stacking between the pyrimidine of dUMP and pyrrolo [2,3-d] pyrimidine, were observed similar to those for CB3717 (Fig. 6 ). The substitution of the thiophene ring for a benzene ring (5) led to similar interactions, but the hydrogen-bond length (3.46 Å) between 4-O and Gly173 was a little longer than that of 4 (3.04 Å). The hydrophobic interactions of the bridge chain moiety of compound 5 seemed enhanced, because the length between C8 and Glu58 was shortened (Fig.  6 ). Based on these considerations compounds 4 and 5 were expected to exhibit potent inhibitory activities against TS.
We further examined the ternary complex model of compound 4, and found that there could be a hydrophobic space surrounded by Glu58, Trp80 and the bridge chain (Fig. 7) . This space existed in the complex model of CB3717 and was not occupied by the propargyl moiety. Filling the space by a hydrophobic moiety was expected to stabilize the binding energy, thus we introduced a hydrophobic substituent at the 8-position of compound 4 [6 (Rϭmethyl), 7 (Rϭethyl), 8 (Rϭvinyl)]. Each of the enantiomers of 6-8 were incorporated in the human TS complex model and examined. These models demonstrated that the length between each substituent at C8 and Glu58 (or Trp80) was shortened and the substituent filled the hydrophobic space efficiently, regardless of the absolute configuration of C8 (Figs. 7, 8 ). In addition, three hydrogen-bonds between the pyrrolo[2,3-d]pyrimidine system and TS were well preserved for 6-8 and the lengths of the hydrogen-bonds were equivalent to those of 4 (Fig. 8) . These results suggested that both the enantiomers of compounds 6-8 could inhibit TS more potently than compound
4.
Recently, a pyrrolo [2,3-d] pyrimidine antifolate with a sulfur bridge and potent inhibitory effect on TS were reported. 22) When this compound was docked into the human TS model, similar interactions were observed such as three hydrogen bonds and the ring stacking with dUMP. However, the sulfur bridge would not be important except for the role as a spacer. Our independently designed compounds are characterized by one carbon bridge, and the fact that they can adopt a hydrophobic substituent on the bridge carbon.
Chemistry
The syntheses of compounds 4-8 are summarized in Charts 1 and 2. The key reaction was the synthesis of the pyrrolo [2,3-d] pyrimidine nucleus by the coupling of 2,6-diamino-4-hydroxypyrimidine with an acyclic precursor a-bromoaldehyde. This reaction was performed using the conditions reported by Secrist III, 23) with some modifications. The key intermediates 10a and 10b for the syntheses of compounds 4 and 5 were prepared from the bromination of propionaldehydes 9a and 9b 8) by 5,5-dibromobarbituric acid (Chart 1). Condensation of 2,6-diamino-4-hydroxypyrimidine (11) and the a-bromoaldehydes 10a and 10b in DMSO containing K 2 CO 3 , gave pyrrolo[2,3-d]pyrimidines 12a and 12b. After acidic deprotection of the tert-butyl ester of 12a and 12b using trifluoroacetic acid (TFA), the resulting benzoic acids were coupled with diethyl L-glutamate using diethyl cyanophosphonate (DEPC). Basic hydrolysis of 13a and 13b with NaOH in H 2 O-THF followed by an acid treatment gave the desired TS inhibitors 4 and 5.
The synthetic pathway of compounds 6-8 is shown in Chart 2. These three compounds 6-8 were synthesized as racemates because they should bind to TS efficiently, regardless of the absolute configuration of C8. Wittig reaction of tert-butyl 4-formylbenzoate 14 with methyl (triphenylphosphoranyliden)acetate gave the cinnamate 15. Treatment of the a,b-unsaturated ester 15 with lithium dimethylcuprate in the presence of trimethylchlorosilane 24) in anhydrous ether afforded the 1,4-addition product 16a. The 1,4-adducts of ethyl 16b or vinyl 16c were synthesized by the conjugate addition using mixed cuprates [PhSCu(RMgBr) n (Rϭethyl or vinyl)] 25) prepared from cuprous thiophenoxide and the Grignard reagent. After selective reduction of methyl esters of The models viewed from two directions are shown. dUMP is shown by brown CPK model and CB3713 by white. The hydrophobic residues around CB3717 are also shown by CPK model. Glu58 and Trp80 are shown by ball-and-stick model. 16a-c using lithium borohydride, the resulting alcohols 17a-c were converted to the corresponding aldehydes 18a-c by Swern's oxidation. The key intermediates 19a-c were prepared by bromination using 5,5-dibromobarbituric acid. The remaining procedures used in the synthesis of the TS inhibitors 6-8 were similar to those for the syntheses of compounds 4 and 5 described above.
Biological Results and Discussion
Compounds 4 to 8 were evaluated for their inhibitory activities against TS purified from mouse fibrosarcoma Meth-A cells ( Table 1 ). The amino acid sequence of the mouse enzyme has high homology (91% identity) to the human TS sequence and the active site region is exactly conserved (Fig.  2) . Thus, it can be assumed that the activity of mouse TS is not significantly different from that of human TS.
Compound 4, with the simple one-carbon bridge, showed moderate activity against TS, and its potency was almost 5-fold higher than that of compound 2 (LY231514) with the two-carbon bridge. Replacement of the benzene ring of 4 with its bioisoster thiophene (5) gave a 12-fold increase of TS inhibitory potency, which may be due to a favorable hydrophobic interaction of the bridge chain moiety caused by the replacement. The introduction of a hydrophobic substituent at C8 of 4 resulted in a 30-60 times improvement (6) (7) (8) . The C8-ethyl analogue 7, the most potent compound (IC 50 ϭ0.017 mM), possessed a 276-fold higher activity than 2 (LY231514). These results indicated that the substituent at C8 established a hydrophobic interaction and filled the unoccupied space created by Glu58, Trp80 and the bridge chain. The docking study to the human TS model was shown to be suitable for the design of potent TS inhibitors.
In conclusion, we designed the unique pyrrolo [2,3-d] pyrimidine TS inhibitors with one-carbon bridge based on the examination of the binding mode of compound 2 to the human TS model. During the course of these studies, five pyrrolo[2,3-d]pyrimidine derivatives (4-8) were synthesized and evaluated for their inhibitory activities against TS. They exhibited more potent TS inhibitory activities than compound 2 (LY231514). These results suggested that our modeling method was effective for designing novel and potent TS inhibitors.
Experimental
Melting points were determined on a Yanagimoto micro melting point apparatus and are uncorrected. 
tert-Butyl 4-[(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl]benzoate (12a)
A mixture of tert-butyl 4-(3-oxopropyl)benzoate (11.52 g) and 5,5-dibromobarbituric acid (7.03 g) in Et 2 O (225 ml) was stirred for 64 h at room temperature. The resulting precipitate was removed by filtration. The filtrate was washed with aqueous Na 2 CO 3 and brine, dried over MgSO 4 and concentrated under vacuum to afford 10a (12.51 g, 65%). To a solution of 2,4-diamino-6-hydroxypyrimidine (11, 1.45 g) in Me 2 SO (6 ml) was added K 2 CO 3 (60 mg), followed by addition of 10a (3.00 g) in Me 2 SO (5 ml). The mixture was stirred for 4 h at room temperature and then poured into water. The resulting precipitate was collected by filtration and purified by flash chromatography (CHCl 3 tert-Butyl 4-(3-Methoxy-1-methyl-3-oxopropyl)benzoate (16a) Under an argon atmosphere methyllithium (1.5 M solution in Et 2 O, 64 ml) was added dropwise to a suspension of copper(I) iodide (9.14 g) in anhydrous Et 2 O at Ϫ40°C. To the solution of Me 2 CuLi were added successively trimethylchlorosilane (6.7 ml) and 15 (10.49 g) in anhydrous Et 2 O (300 ml) at Ϫ78°C. The stirred mixture was allowed to warm slowly up to room temperature (1 h). Stirring was continued at room temperature for 2 h, then hydrolyzed with aqueous NH 4 Cl. The aqueous layer was extracted with Et 2 O. The combined ether layer was washed with brine, dried over MgSO 4 and concentrated under vacuum. The residue was purified by flash chromatography (n-hexane/AcOEt, 95 : 5) to afford 16a (4.36 g, 39%) tert-Butyl 4-(3-Hydroxy-1-methylpropyl)benzoate (17a) Lithium borohydride (348 mg) was added to a solution of 16a (4.24 g) in anhydrous Et 2 O (30 ml). After the mixture was stirred at room temperature for 13 h, the reaction was quenched with 1 N aqueous KHSO 4 tert-Butyl 4-(1-Methyl-3-oxopropyl)benzoate (18a) Under an argon atmosphere a solution of DMSO (2.57 g) in CH 2 Cl 2 (35 ml) was added to a solution of oxalyl chloride (2.09 g) in CH 2 Cl 2 (70 ml) at Ϫ60°C. After 2 min, a solution of 17a (3.43 g) in CH 2 Cl 2 (30 ml) was added. Stirring was continued at Ϫ60°C for 15 min, and then triethylamine (6.93 g) was added. The mixture was allowed to warm to 0°C in 30 min, and poured into water (350 ml). The aqueous phase was extracted with CH 2 Cl 2 . The combined organic phase was dried over MgSO 4 and concentrated under vacuum. Purification by flash chromatography (n-hexane/AcOEt, 5 : 1) gave 18a (3.16 g, 93%) Preparation of Crude TS A crude fraction of TS was prepared from Meth-A fibrosarcoma cells. Meth-A cells (2ϫ10 4 ml), in 2.0 l of Eagle's minimum essential medium (MEM) supplemented with 10% fetal bovine serum (FBS), were divided into ten culture flasks and incubated for 72 h at 37°C in 5% CO 2 . Cells were washed twice in phosphate-buffered saline and resuspended in 5 ml of 250 mM sucrose, 10 mM Tris-HCl buffer (ph 7.5), and then disrupted ultrasonically. Cell lysate was centrifuged at 100000ϫg for 1 h at 4°C. The cytosol fraction (crude TS fraction) was diluted with 250 mM sucrose and 10 mM Tris-HCl buffer (pH 7.5) to adjust the protein concentration to 10 mg/ml and then it was stored at Ϫ20°C.
TS Inhibition Assay TS activity was measured by the method of Roberts 26) with some modification. In brief, 10 ml of crude TS fraction was added to 40 ml of reaction mixture in a flat-bottom 96 well plate, in triplicate. The final concentrations of the constituents of the reaction mixture were as follows; 800 mM tetrahydrofolic acid, 18 mM formaldehyde, 80 mM dUMP, 0.51 mM [
3 H]dUMP, 10.2 mM 2-mercaptoethanol, 100 mM sucrose, 68 mM NaF, 174 mM Tris-HCl (pH 7.5), 6.24 mg/ml bovine serum albumin and various concentrations of test compounds. The reaction mixture was incubated on a water bath at 37°C for 1 h and then chilled on ice. Ice cold 26.65% trichloroacetic acid (20 ml), 3.33 mg/ml cold dUMP (10 ml) and 114 mg/ml charcoal (220 ml) were added to the reaction mixture, which was then transferred to a centrifuge tube. After centrifugation, the amount of [
